NasdaqCM - Nasdaq Real Time Price USD

FibroBiologics, Inc. (FBLG)

0.9300 +0.0070 (+0.76%)

At close: October 30 at 4:00:00 PM EDT

Chart Range Bar

Loading chart for FBLG

Previous Close 0.9230
Open 0.9200
Bid 1.1700 x 100
Ask 1.4600 x 100
Day's Range 0.9000 - 0.9696
52 Week Range 0.6200 - 9.6000
Volume 20,671
Avg. Volume 213,285
Market Cap (intraday) 6.586M
Beta (5Y Monthly) 1.84
PE Ratio (TTM) --
EPS (TTM) -5.0100
Earnings Date (est.) --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est 12.50

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

fibrobiologics.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FBLG

79.33%

S&P 500 (^GSPC)

10.73%

1-Year Return

FBLG

88.29%

S&P 500 (^GSPC)

11.11%

3-Year Return

FBLG

99.85%

S&P 500 (^GSPC)

81.91%

5-Year Return

FBLG

99.85%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -4.12M

Profit Margin 0.00%

FY25

FY26

-4M

-2M

0.0%

Analyst Price Targets

6.00

12.50 Average

0.9300 Current

19.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 8/4/2026

Analyst HC Wainwright & Co.

Rating Action Maintains

Rating Buy

Price Action Lowers

Price Target 8 -> 6

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-95.77%
Return on Equity (ttm)

-660.08%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-18.14M
Diluted EPS (ttm)

-5.0100

Balance Sheet and Cash Flow

Total Cash (mrq)

3.52M
Total Debt/Equity (mrq)

31.54%
Levered Free Cash Flow (ttm)

-8.37M

CLDI Calidi Biotherapeutics, Inc.

0.6880 +2.43%

GUTS Fractyl Health, Inc.

0.9765 -1.51%

SXTP 60 Degrees Pharmaceuticals, Inc.

0.9400 -0.79%

TELO Telomir Pharmaceuticals, Inc.

0.9352 -3.01%

AZTR Azitra, Inc.

0.7692 +1.60%

U.S. markets open in 2h 49m

FibroBiologics, Inc. (FBLG)

-2.11%

-28.46%

-29.55%

-79.33%

-88.29%

-99.85%

-99.85%

FibroBiologics, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch